C
Changqing Bai
Publications - 4
Citations - 6852
Changqing Bai is an academic researcher. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 1 publications receiving 5215 citations.
Papers
More filters
Journal ArticleDOI
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Zhe Xu,Lei Shi,Yijin Wang,Ji-Yuan Zhang,Lei Huang,Chao Zhang,Shuhong Liu,Peng Zhao,Hongxia Liu,Li Zhu,Yanhong Tai,Changqing Bai,Tingting Gao,Jin-Wen Song,Peng Xia,Jing-Hui Dong,Jingmin Zhao,Fu-Sheng Wang +17 more
TL;DR: O surto do novo coronavÃrus (COVID-19) em Wuhan, China, iniciado em dezembro de 2019, evoluiu para se tornar uma pandemia global A.
Journal ArticleDOI
Characterization and Genomic Analysis of Bacteriophage vB_KpnM_IME346 Targeting Clinical Klebsiella pneumoniae Strain of the K63 Capsular Type
Mingming Gao,Lingxian Yi,Yuanyuan Wang,Jie Gao,Huiying Liu,Xianglilan Zhang,Guangqian Pei,Yigang Tong,Changqing Bai +8 more
TL;DR: In this paper , a Klebsiella pneumoniae bacteriophage (vB_KpnM_IME346) was isolated from a hospital sewage sample, which revealed a linear double-stranded DNA genome consisting of 49,482 base pairs with a G+C content of 49.1%.
Journal ArticleDOI
Legionella sainthelensi Pneumonia with Abdominal Symptoms as Prominent Manifestations
Xin Yuan,Fang-Fang Meng,Xinting Yu,Changqing Bai,Rui Jia,Fanping Meng,Fu-Sheng Wang,Junliang Fu +7 more
TL;DR: In this article , an immunocompromised patient with cavitary pneumonia caused by Legionella sainthelensi had abdominal distension and liver function impairment, and the timely administration of moxifloxacin provided clinical improvement and resolution of symptoms.
Journal ArticleDOI
Macrophage‐based delivery of anti‐fibrotic proteins alleviates bleomycin‐induced pulmonary fibrosis in mice
Huiying Liu,Yun Gao,Xueli Zhang,Min Wang,Xinting Yu,Weidong Wang,Lixin Xie,Ping Tang,Xiushan Yin,Changqing Bai,Luo Zhang +10 more
TL;DR: In this paper , an innovative macrophage-based approach was described to deliver anti-fibrotic protein to the lung and inhibit IPF in a mouse model of bleomycin (BLM)-induced lung injury.